Genpact G Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value at other companies

CHE

ChemedCHE

85.8-25.1%

BeldenBDC

$39.44+80.5%

RepligenRGEN

$129.34—

SS&C TechnologiesSSNC

$97.28+43.3%

RepligenRGEN

$65.80-18.2%

VeriSignVRSN

$226.12+16.1%

Other financials

Income statement

See full

Revenue$1.3B+6.7%

Gross profit$471.7M+9.9%

Operating income$198.6M+8.1%

Net income$148.0M+13.1%

EPS (diluted)$0.86+17.8%

Balance sheet

See full

Cash & equivalents$578.1M+2.9%

Total debt$1.4B-4.9%

Total equity$2.5B+0.9%

Total assets$5.6B+14.8%

Cash flow

See full

Operating cash flow-$23.5M-158%

CapEx$23.9M+8.9%

Free cash flow-$47.5M-357%

Valuation

See full

Market cap$4.79B-28.5%

Profitability

See full

Gross margin36.3%+0.8pp

Operating margin14.8%-0.1pp

Net margin11%+0.2pp

FCF margin13%+0.6pp

Returns & leverage

See full

Return on equity23.1%+0.9pp

Debt / equity0.6×0.0×

Current ratio1.7×-0.8×

Where this comes from

Reported directly by Genpact in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue.

The official record: Genpact’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Genpact's share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Genpact's share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value?: Genpact (G) reported share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value of $0.00 in Q1 2026.